Senseonics Reports 36.6% Revenue Growth to $6.6 Million in Q2 2025

Senseonics Holdings, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2025. The company achieved total revenue of $6.6 million for the quarter, a 36.6% increase from $4.9 million in the same period last year. This growth was primarily driven by increased sales of its Eversense continuous glucose monitoring systems, particularly through a consignment program. For the first half of 2025, total revenue reached $12.9 million, up from $9.9 million in the prior year, reflecting a 30.2% increase. Despite the revenue growth, the company reported a net loss of $14.5 million for the quarter, an improvement from a loss of $20.3 million in the same quarter of 2024.

The company’s operational metrics showed a notable shift, with gross profit rising to $3.1 million for the second quarter, compared to $298,000 in the previous year, resulting in a gross margin of 46.9%. This improvement was attributed to favorable margins on the new 365-day product, lower fixed manufacturing costs, and a one-time recovery of previously expensed value-added tax. Research and development expenses decreased to $7.7 million from $10.8 million year-over-year, reflecting reduced costs associated with completed clinical trials for the Eversense 365 system. Selling, general, and administrative expenses increased slightly to $9.7 million, driven by higher sales commissions linked to increased consignment sales.

In terms of strategic developments, Senseonics completed a public offering on May 15, 2025, raising approximately $57.5 million by selling 100 million shares at $0.50 each. Additionally, the company entered into a private placement with Abbott Laboratories, generating another $20.3 million. These financing activities have bolstered the company’s liquidity, with unrestricted cash, cash equivalents, and marketable securities totaling $126.4 million as of June 30, 2025. The company also reported a significant reduction in total liabilities, which decreased to $55.6 million from $79.3 million at the end of 2024.

Operationally, Senseonics has focused on expanding its market presence and product adoption. The company has established a network of healthcare professionals for the consignment sale of its products, which accounted for 40.9% of total revenue in the second quarter of 2025, up from 14.7% in the same quarter of 2024. The company is also in the early stages of commercialization for its Eversense 365 system, which received FDA approval in September 2024. Looking ahead, Senseonics aims to continue its growth trajectory by enhancing product awareness and expanding insurance coverage for its glucose monitoring systems, while managing operational costs effectively.